Curative therapy for bladder cancer in routine clinical practice: A population-based outcomes study

Clinical Oncology

Volumn 26, Issue 8, 2014, Pages 506-514

  Booth, C M ^a,b   Siemens, D R ^b   Li, G ^a   Peng, Y ^a,b   Kong, W ^a   Berman, D M ^b   Mackillop, W J ^a,b  

^a QUEEN S UNIVERSITY   (Canada)

^b QUEEN S UNIVERSITY   (Canada)

Author keywords

Bladder cancer; Cystectomy; Health services; Outcomes; Quality of care; Radiation

Indexed keywords

ADULT; AGED; ARTICLE; BLADDER CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CANCER THERAPY; CLINICAL PRACTICE; COHORT ANALYSIS; COMORBIDITY; CYSTECTOMY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; MIDDLE AGED; SURVIVAL; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; COHORT STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS; YOUNG ADULT;

EID: 84903815203     PISSN: 09366555     EISSN: 14332981     Source Type: Journal    
DOI: 10.1016/j.clon.2014.05.007     Document Type: Article

References (32)

1. Stein J.P., Lieskovsky G., Cote R., et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. JClin Oncol 2001, 19(3):666-675.
2. Rodel C., Grabenbauer G.G., Kuhn R., et al. Combined-modality treatment and selective organ preservation in invasive bladder cancer: long-term results. JClin Oncol 2002, 20(14):3061-3071.
3. Malkowicz S.B., van P.H., Mickisch G., et al. Muscle-invasive urothelial carcinoma of the bladder. Urology 2007, 69(1 Suppl.):3-16.
4. Bellmunt J., Albiol S., Kataja V. Invasive bladder cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2009, 20(Suppl. 4):79-80.
5. Stenzl A., Cowan N.C., De S.M., et al. Treatment of muscle-invasive and metastatic bladder cancer: update of the EAU guidelines. Eur Urol 2011, 59(6):1009-1018.
6. National Comprehensive Cancer Network NCCN Guidelines Bladder Cancer 2012, Available at:, [accessed 27.05.13]. http://www.nccn.org/professionals/physician_gls/pdf/bladder.pdf.
7. Scottish Intercollegiate Guidelines Network Management of transitional cell carcinoma of the bladder: a national clinical guideline 2005, National Health Service, Edinburgh, Available at:, [accessed 27.05.13]. http://www.sign.ac.uk/guidelines/fulltext/85/index.html.
8. Booth C.M., Mackillop W.J. Translating new medical therapies into societal benefit: the role of population-based outcome studies. JAMA 2008, 300(18):2177-2179.
9. Hayter C.R., Paszat L.F., Groome P.A., Schulze K., Mackillop W.J. The management and outcome of bladder carcinoma in Ontario, 1982-1994. Cancer 2000, 89(1):142-151.
10. Scrimger R.A., Murtha A.D., Parliament M.B., et al. Muscle-invasive transitional cell carcinoma of the urinary bladder: a population-based study of patterns of care and prognostic factors. Int J Radiat Oncol Biol Phys 2001, 51(1):23-30.
11. Munro N.P., Sundaram S.K., Weston P.M., et al. A10-year retrospective review of a nonrandomized cohort of 458 patients undergoing radical radiotherapy or cystectomy in Yorkshire, UK. Int J Radiat Oncol Biol Phys 2010, 77(1):119-124.
12. Kozak K.R., Hamidi M., Manning M., Moody J.S. Bladder preservation for localized muscle-invasive bladder cancer: the survival impact of local utilization rates of definitive radiotherapy. Int J Radiat Oncol Biol Phys 2012, 83(2):e197-e204.
13. Clarke E.A., Marrett L.D., Krieger N. Cancer registration in Ontario: a computer approach. Cancer registration principles and methods 1991, 246-257. IARC, Lyon. O.M. Jenson, D.M. Parkin, R. MacLennan (Eds.).
14. Booth C.M., Li G., Zhang-Salomons J., Mackillop W.J. The impact of socioeconomic status on stage of cancer at diagnosis and survival: a population-based study in Ontario, Canada. Cancer 2010, 116(17). 4160-4167.
15. Williams J., Young W. Asummary of studies on the quality of health care administrative databases in Canada. Patterns of health care in Ontario: the ICES practice atlas 1996, 339-345. Canadian Medical Association, Ottawa. V. Goel, J.I. Williams, G.M. Anderson (Eds.).
16. Mackillop W.J., Fu H., Quirt C.F., Dixon P., Brundage M., Zhou Y. Waiting for radiotherapy in Ontario. Int J Radiat Oncol Biol Phys 1994, 30(1):221-228.
17. Deyo R.A., Cherkin D.C., Ciol M.A. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. JClin Epidemiol 1992, 45(6):613-619.
18. Earle C.C., Tsai J.S., Gelber R.D., Weinstein M.C., Neumann P.J., Weeks J.C. Effectiveness of chemotherapy for advanced lung cancer in the elderly: instrumental variable and propensity analysis. JClin Oncol 2001, 19(4):1064-1070.
19. Rubin D.B. Estimating causal effects from large data sets using propensity scores. Ann Intern Med 1997, 127(8 Pt 2):757-763.
20. Madersbacher S., Hochreiter W., Burkhard F., et al. Radical cystectomy for bladder cancer today - a homogeneous series without neoadjuvant therapy. JClin Oncol 2003, 21(4):690-696.
21. Hautmann R.E., Gschwend J.E., de Petriconi R.C., Kron M., Volkmer B.G. Cystectomy for transitional cell carcinoma of the bladder: results of a surgery only series in the neobladder era. JUrol 2006, 176(2):486-492.
22. Shariat S.F., Karakiewicz P.I., Palapattu G.S., et al. Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: a contemporary series from the Bladder Cancer Research Consortium. JUrol 2006, 176(6 Pt 1):2414-2422.
23. Milosevic M., Gospodarowicz M., Zietman A., et al. Radiotherapy for bladder cancer. Urology 2007, 69(1 Suppl.):80-92.
24. Birkmeyer J.D., Sun Y., Wong S.L., Stukel T.A. Hospital volume and late survival after cancer surgery. Ann Surg 2007, 245(5):777-783.
25. Hayter C.R., Paszat L.F., Groome P.A., Schulze K., Math M., Mackillop W.J. Apopulation-based study of the use and outcome of radical radiotherapy for invasive bladder cancer. Int J Radiat Oncol Biol Phys 1999, 45(5):1239-1245.
26. Schrag D., Mitra N., Xu F., et al. Cystectomy for muscle-invasive bladder cancer: patterns and outcomes of care in the Medicare population. Urology 2005, 65(6):1118-1125.
27. Snyder C., Harlan L., Knopf K., Potosky A., Kaplan R. Patterns of care for the treatment of bladder cancer. JUrol 2003, 169(5):1697-1701.
28. Gore J.L., Litwin M.S., Lai J., et al. Use of radical cystectomy for patients with invasive bladder cancer. JNatl Cancer Inst 2010, 102(11):802-811.
29. Shelley M.D., Barber J., Wilt T., Mason M.D. Surgery versus radiotherapy for muscle invasive bladder cancer. Cochrane Database Syst Rev 2002, (1):CD002079.
30. Huddart R.A., Hall E., Lewis R., Birtle A. Life and death of spare (selective bladder preservation against radical excision): reflections on why the spare trial closed. BJU Int 2010, 106(6):753-755.
31. James N.D., Hussain S.A., Hall E., et al. Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer. NEngl J Med 2012, 366(16):1477-1488.
32. Booth C.M., Siemens D.R., Li G., et al. Peri-operative chemotherapy for muscle-invasive bladder cancer: a population-based outcomes study. Cancer 2014, 120(11):1630-1638.